report fiscal adjust ep
consensu expect higher forecast lower-than-
anticip adjust tax rate account upsid rel
adjust ep forecast revenu adjust gross margin net interest
expens also modestli stronger expect
coo fiscal revenu increas year-over-year million
consensu expect million estim
million quarter coopersurg achiev pro forma organ
growth well forecast led high-single-digit pro forma
organ growth offic surgic product well fertil addit
coopervis deliv organ growth similar estim
strength asia pacif pro forma basi emea
pro forma basi aid compani key account initi help
off-set soft america pro forma basi
year similar estim quarter
compani invest distribut center upgrad sale forc addit
market expens paragard contribut bp increas
adjust sg expens percent sale expens
also higher anticip howev off-set strength
adjust gross margin favor paragard sale product mix chang
coopervis aid fiscal result
rais revenu guidanc million
million versu consensu expect million
compani revis outlook reflect slightli stronger pro forma growth
coopervis versu previous benefit two
acquisit blanchard contact lens inc incis surgic utah
medic decis buy back distribut right filshi clip
modestli stronger currenc growth expect addit
increas adjust ep guidanc
versu consensu expect along improv
reduc adjust tax rate versu previous lower ep
headwind currenc neg versu neg previous
total debt total asset
rais adjust ep estim
reflect upsid fiscal encourag improv trend
coopersurg notabl earli respons increas market
effort paragard addit remain comfort coo key account
initi intermediate-term opportun misight myopia control
drive sustain above-market organ growth coopervis
maintain buy rate rais price target
import pleas read disclosur disclaim page report
report fiscal adjust ep consensu expect higher
forecast lower-than-anticip adjust tax rate versu estim account
upsid rel adjust ep forecast revenu adjust gross margin net interest
expens also modestli stronger expect
coo fiscal revenu increas year-over-year million consensu
expect million estim million quarter total compani organ growth
roughli estim led strength coopersurg addit acquisit growth
approxim slightli better anticip aid modest contribut januari
cooper compani incfisc adjust incom statement revenu analysisnorthcoast research thousand except percentag per share gross gross sg sg oper oper net interest incom interest incom incom incom incom tax adjust net adjust net net net wghd com share ep ep revenu growth adjust ep growth analysi revenu compani report northcoast research estim factset incis surgic acquisit contrast revenu contribut currenc chang slightli wors
model million versu million forecast
divis standpoint coopervis achiev fiscal organ growth approxim
slightli estim
quarter coopervis result led strength asia pacif pro forma basi emea
pro forma basi aid compani key account initi help off-set soft
america pro forma basi note overal contact len market slower calendar
alcon also experienc weak quarter said world-wide trend remain
strong suggest market growth reach led mix shift daili silicon hydrogel
lens versu typic rate rang similar market coopervis sale daili silicon
hydrogel lens particularli strong fiscal year-over-year pro forma organ growth
basi combin sale silicon hydrogel lens biofin avaira also improv year-over-
coopersurg report fiscal pro forma organ growth exclud carrier screen
non-invasive prenat test prior year revenu estim coopersurg fiscal organ growth
closer well forecast quarter compani fertil busi
return posit organ growth includ impact discontinu product move past
disrupt creat exit carrier screen non-invasive prenat test addit fiscal
strong quarter coopersurg core offic surgic product achiev roughli growth led
improv paragard sale mid-single-digit growth offic surgic product notabl
coo increas market effort paragard appear reson field
coo fiscal adjust oper margin declin bp year-over-year similar
estim quarter compani invest distribut center upgrad sale forc addit
market expens paragard contribut bp increas adjust sg expens percent
sale expens also higher anticip howev off-set strength adjust
gross margin favor paragard sale product mix chang coopervis aid fiscal result
rais revenu guidanc million million versu consensu
expect million compani revis outlook reflect slightli stronger pro forma growth
coopervis versu previous benefit two acquisit blanchard contact lens inc
coopervisionquarterli revenu growth analysisnorthcoast research million except daili sihi organ growth daili sihi compani report northcoast research estimatescoopersurg inc organ growth analysissourc compani report northcoast research flat incis surgic utah medic decis buy back distribut right filshi clip system
modestli stronger currenc growth expect addit increas adjust ep guidanc
versu consensu expect along improv revenu
outlook coo revis adjust ep guidanc assum benefit reduc adjust tax rate versu
previous lower ep headwind currenc neg versu neg previous fewer
fiscal expect adjust ep lower compani previous anticip
pull forward roughli million plan fiscal market expens paragard fiscal
note pleasantli surpris earli respons increas market activ
paragard want concentr spend first half year better understand impact
effort evalu market program fiscal decid want proceed
paragard market effort
summari rais adjust ep estim reflect compani
upsid fiscal encourag improv trend coopersurg notabl earli
respons increas market effort paragard addit remain comfort coo key account
initi intermediate-term opportun misight myopia control drive sustain above-market
organ growth coopervis maintain buy rate rais price target
cooper compani guidanc earn earn million coopervis million coopersurg revenu impact currencyneg millionneg adjust gross marginup modestli year-over-yearup modestli adjust oper marginup modestli year-over-yearup modestli net interest expensethre fed rate increasestwo fed rate adjust tax adjust adjust ep impact currencyneg compani report northcoast research
cooper compani inc annual incom statement analysi adjust northcoast research thousand except percent per share gross gross sg sg oper oper net interest interest incom incom incom incom tax minor net incom extra net margin extra extra net net wghd com share ep ep revenu growth adjust ep growth began exclud amort intang adjust ep follow sauflon acquisitionsourc compani report northcoast research estim disclosur
